Skip to main content
OpenTrials
Completed

NCT Number: NCT00353431

Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia

The aim of this study is to test the safety and efficacy of a new algorithm for intensive s.c. insulin injection in medical emergency patients with hyperglycaemia (plasma glucose concentration ≥ 8 mmol/l)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Division of Endocrinology, Diabetes & Clinical Nutrition, Dept of Internal Medicine,

Basel, Canton of Basel-City, 4031, Switzerland

About this study

BACKGROUND: Prospective randomized trials have shown that near-normoglycemic blood glucose control using insulin infusions achieves a significant reduction in mortality of severely ill patients in intensive care units, of patients with acute myocardial infarction and with stroke. This implies that most severely ill patients with hyperglycemia should be treated with insulin to reach near-normoglycemia. However, this is not common practice today in emergency room admissions outside the intensive care unit, and strategies to achieve near-normoglycemia safely outside the ICU setting with s.c. injections (insulin infusions are too risky outside the ICU) have not been established.

AIM: To evaluate an insulin therapy algorithm using s.c. injections which permits effective and safe glycemic management of emergency room patients with hyperglycemia.

DESIGN: Randomized, controlled trial with an open intervention. Patients presenting with hyperglycemia on admission to the emergency room are randomized 1:1 either to conventional treatment (conventional insulin group) or to intensive treatment (intensive insulin group).

METHODS: 140 patients admitted to the medical emergency rooms of the University Hospital Basel and the Regional Hospital of Solothurn will be included and randomized as described above. All patients with plasma glucose levels exceeding 8.0 mmol/l will be included.

Exclusion criteria

include severely immunocompromised patients, patients in shock, patients with terminal illnesses on palliative care, type 1 diabetes with or without ketoacidosis and patients which require intensive care unit (ICU) or cardial care unit (CCU) therapy.

PRIMARY ENDPOINT: Time in the glycaemic target range (5.5-7.0 mmol/l) during the period of observation of 48 hours (expected to be longer in the intensive insulin group)

SECONDARY ENDPOINTS: Time to reach the target range. Frequency of hypoglycaemia (plasma glucose < 3.8 mmol/l). Frequency of severe hypoglycaemia (plasma glucose < 2.5 mmol/l. Frequency of hypokalaemia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • all patients with hyperglycaemia (≥ 8.0 mmol/l) admitted to the medical emergency room.
  • patients with presumed hospitalisation in ER or medical ward of more than 48 h duration.

Exclusion criteria

  • patients in shock (defined as hypotension or shock index > 1 with oliguria, changed mental status and metabolic acidosis)
  • patients with a terminal illness on palliative care
  • patients with type 1 diabetes
  • patients with insulin pump therapy
  • patients with need for hospitalisation in the intensive or coronary care unit.
  • patients with presumed hospitalisation shorter than 48 hours
  • known pregnancy (in women with childbearing potential pregnancy test for exclusion mandatory)
  • no informed consent

Treatment and study plan

Novorapid ®, Novo Nordisk, Denmark

Drug

Comparison of a sliding scale with an intensive s.c. scale

Other names: insulin aspart,, Novolog

Primary outcomes

  1. Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours

    Time frame: 48 h

    Hours in which the plasma glucose was between 5.5 and 7.0 mmol/l (expected to be longer in the intensive insulin group)

Secondary outcomes

  1. Time to Reach the Target Range

    Time frame: 24 h

    Hours needed to reach 5.5.-7.0 mmol/l (expected to be shorter in the intensive insulin group).

  2. Frequency of Hypoglycemia

    Time frame: during observation of 48 hours

    absolute number of participants with hypoglycemia (plasma glucose < 3.8 mmol/l) (safety endpoint, expected to be similar in the two groups)

  3. Frequency of Severe Hypoglycaemia

    Time frame: during observation of 48 hours

    Number of participants with severe hypoglycaemia (plasma glucose < 2.5 mmol/l) (safety endpoint, expected to be similar in the two groups)

  4. Frequency of Hypokalaemia

    Time frame: during observation of 48 hours

    Number of participants with hypokalaemia (potassium < 3.6 mmol/l, safety endpoint, expected to be similar in the two groups)

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Important dates

Study start
2006
Primary completion
2010
Study completion
2010
First posted
Jul 18, 2006
Registry last updated
May 18, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.